Arcellx Inc. (ACLX)
65.77
2.48 (3.92%)
At close: Feb 20, 2025, 3:59 PM
65.61
-0.24%
After-hours: Feb 20, 2025, 04:00 PM EST
undefined% (undefined)
| Bid | 62.62 |
| Market Cap | 3.56B |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | -0.71 |
| PE Ratio (ttm) | -92.63 |
| Forward PE | n/a |
| Analyst | Buy |
| Ask | 68.18 |
| Volume | 513,588 |
| Avg. Volume (20D) | 597,145 |
| Open | 63.25 |
| Previous Close | 63.29 |
| Day's Range | 62.41 - 66.39 |
| 52-Week Range | 47.88 - 107.37 |
| Beta | undefined |
About ACLX
Arcellx, Inc., a clinical-stage biotechnology company, engages in the development of various immunotherapies for patients with cancer and other incurable diseases. The company's lead ddCAR product candidate is CART-ddBCMA, which is in phase 1 clinical trial for the treatment of patients with relapsed or refractory (r/r) multiple myeloma (MM). It is also developing ACLX-001, an immunotherapeutic combination composed of ARC-T cells and bi-valent Sp...
Industry Biotechnology
Sector Healthcare
IPO Date Feb 4, 2022
Employees 130
Stock Exchange NASDAQ
Ticker Symbol ACLX
Website https://arcellx.com
Analyst Forecast
According to 13 analyst ratings, the average rating for ACLX stock is "Buy." The 12-month stock price forecast is $114, which is an increase of 73.33% from the latest price.
Buy 100.00%
Hold 0.00%
Sell 0.00%
Next Earnings Release
Arcellx Inc. is scheduled to release its earnings on Mar 3, 2025,
during market hours.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
3 months ago
+0.79%
Acrellx shares are trading lower after the company...
Unlock content with
Pro Subscription
6 months ago
+12.31%
Arcellx shares are trading higher after the company reported better-than-expected Q2 financial results.
